Trial watch: Naked and vectored DNA-based anticancer vaccines

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294959" target="_blank" >RIV/00216208:11130/15:10294959 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10294959

Výsledek na webu

<a href="http://dx.doi.org/10.1080/2162402X.2015.1026531" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1026531</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2015.1026531" target="_blank" >10.1080/2162402X.2015.1026531</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Trial watch: Naked and vectored DNA-based anticancer vaccines

Popis výsledku v původním jazyce

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is to drive the synthesis of TAAs in the context of an immunostimulatory milieu, resulting in the (re-)elicitation of a tumor-targeting immune response. In spite of encouraging preclinical results, the clinical efficacy of DNA-based vaccinesemployed as standalone immunotherapeutic interventions in cancer patients appears to be limited. Thus, efforts are currently being devoted to the development of combinatorial regimens that allow DNA-based anticancer vaccines to elicit clinically relevantimmune responses. Here, we discuss recent advances in the preclinical and clinical development of this therapeutic paradigm.

Název v anglickém jazyce

Trial watch: Naked and vectored DNA-based anticancer vaccines

Popis výsledku anglicky

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is to drive the synthesis of TAAs in the context of an immunostimulatory milieu, resulting in the (re-)elicitation of a tumor-targeting immune response. In spite of encouraging preclinical results, the clinical efficacy of DNA-based vaccinesemployed as standalone immunotherapeutic interventions in cancer patients appears to be limited. Thus, efforts are currently being devoted to the development of combinatorial regimens that allow DNA-based anticancer vaccines to elicit clinically relevantimmune responses. Here, we discuss recent advances in the preclinical and clinical development of this therapeutic paradigm.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OncoImmunology [online]

ISSN

2162-402X

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000354985400022

EID výsledku v databázi Scopus

—